Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
Summary
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma is a scholarly article[1].
Key Facts
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Retrieved May 24, 2026, from https://4ort.xyz/entity/elranatamab-efficacy-in-magnetismm-3-compared-with-real-world-control-arms-in-triple-class-refractory-multiple-myeloma
MLA“Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/elranatamab-efficacy-in-magnetismm-3-compared-with-real-world-control-arms-in-triple-class-refractory-multiple-myeloma.
BibTeX@misc{4ortxyz_elranatamab-efficacy-in-magnetismm-3-compared-with-real-world-control-arms-in-triple-class-refractory-multiple-myeloma_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma}}, year = {2026}, url = {https://4ort.xyz/entity/elranatamab-efficacy-in-magnetismm-3-compared-with-real-world-control-arms-in-triple-class-refractory-multiple-myeloma}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma — https://4ort.xyz/entity/elranatamab-efficacy-in-magnetismm-3-compared-with-real-world-control-arms-in-triple-class-refractory-multiple-myeloma (retrieved 2026-05-24)
